A newly validated set of patient-reported outcomes in hemophilia correlate well with social and demographic data. Findings may help individualize care and optimize patient well-being.
Cleveland Clinic researchers are first to test pomalidomide for refractory bleeding in hereditary hemorrhagic telangiectasia. Interim data signals reduced bleeding and reduced need for transfusions.
Tetrahydrouridine renders decitabine orally bioavailable at nontoxic doses in first-in-human trial, safely increasing fetal hemoglobin (HbF) up to twofold in patients with sickle cell disease.
More than 5,000 patients came to Cleveland Clinic from all over the world for electrophysiology lab procedures in 2015. This two-minute video shares a few reasons why.
Leonard Calabrese, DO, Director of the RJ Fasenmyer Center for Clinical Immunology, reflects on breakthroughs in vasculitis at the 2016 American College of Rheumatology meeting.
It’s time to systematically focus on real functional improvements for patients with chronic low back pain rather than opting for premature quick fixes. A new Cleveland Clinic pilot program leads the way.
Ketamine for treatment-resistant depression will be the No. 7 most influential medical innovation in 2017, predict experts at Cleveland Clinic.
At Cleveland Clinic, a dedicated off-site central monitoring unit (CMU) provides 24/7 cardiac telemetry monitoring for non-critically ill patients. Standardized criteria and the latest technology is new to the world of telemetry.
The development and availability of biologic agents to target specific pathophysiological elements of severe asthma has altered the landscape of care. Our asthma experts break down biologic use for patients with severe asthma.
Reducing the rate of readmissions can be a costly proposition. This study validates the effectiveness of an easy-to-use readmission risk prediction tool in the skilled nursing facility setting that can help allocate resources effectively and keep costs down.